Search Results
Sep 08, 2026, 08:00 ET Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
conditionsTITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026
More news about: Johnson & Johnson
Aug 24, 2026, 19:12 ET FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
patientsdSPRING HOUSE, Pa., Aug. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic
More news about: Johnson & Johnson
Jul 30, 2026, 10:31 ET Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
bowel disease therapies in clinical trials include ABX464 (obefazimod), Tulisokibart (MK-7240), RHB-204, TEV-574 (duvakitug), AGMB-129, Olamkicept, JNJ-4804 Co-antibody Therapy, Zotemtegrast, ATH-063, SPY001, SPY002, SPY003, DB-3Q, Zasocitinib, ABBV-243, ABBV-701, TRX103, XmAb412, and others.Discover
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
journeyRARITAN, N.J., July 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study
More news about: Johnson & Johnson
Jul 21, 2026, 09:00 ET A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
Pathways (NASDAQ: CMPS), GH Research (NASDAQ: GHRS), Definium Therapeutics (NASDAQ: DFTX), and Johnson & Johnson (NYSE: JNJ) all advancing or commercializing novel approaches to difficult-to-treat depression.Enrollment Wrapped Early on a Closely Watched Depression
More news about: USA News Group
Jul 21, 2026, 08:30 ET Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
and Company (NYSE: LLY), AtaiBeckley Inc. (NASDAQ: ATAI), Compass Pathways plc (NASDAQ: CMPS), Johnson & Johnson (NYSE: JNJ).
More news about: Market News Updates
Jun 26, 2026, 12:35 ET Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
(gMG)GENEVA, June 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of
More news about: Johnson & Johnson
Jun 18, 2026, 17:08 ET Johnson & Johnson recebe aprovação da Anvisa para TECVAYLI® (teclistamabe) em combinação com DALINVI® (daratumumabe) subcutâneo (SC) para mieloma múltiplo recidivado ou refratário, ampliando as opções de tratamento disponíveis para pacientes a partir da primeira recaída.
tratamentoSÃO PAULO, 18 de junho de 2026 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ) anunciou que recebeu aprovação regulatória da Agência Nacional de Vigilância Sanitária (Anvisa) para o TECVAYLI® (teclistamabe) em combinação com DALINVI®
More news about: Johnson & Johnson Innovative Medicine Brazil
Jun 18, 2026, 12:31 ET Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight
development include Seltorexant (JNJ-42847922) (Johnson & Johnson), HETLIOZ (tasimelteon) (Vanda Pharmaceuticals), Daridorexant (Idorsia), SM-1 (EUSOL Biotech), and others.Janssen Pharmaceutical's seltorexant (JNJ-42847922) is a selective orexin-2 receptor
More news about: DelveInsight Business Research, LLP
Jun 11, 2026, 02:03 ET IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
STOCKHOLM, June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically
More news about: Johnson & Johnson
Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
damageLONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b
More news about: Johnson & Johnson
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjögren's
More news about: Johnson & Johnson
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
indication CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses
More news about: Johnson & Johnson
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Res. 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833 9 Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol
More news about: Johnson & Johnson
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
betterCHICAGO, May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and
More news about: Johnson & Johnson
May 28, 2026, 19:10 ET FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
arthritisHORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence
More news about: Johnson & Johnson
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
solid tumors: Preliminary results from the FIT-001 phase 1 first-in-human trial.A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.Intismeran
More news about: Florida Cancer Specialists & Research Institute
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
2025.Separately, at the American Association for Cancer Research (AACR) Annual Meeting, Johnson & Johnson disclosed JNJ‑95437446, an amivantamab-based EGFR/MET ADC that uses CPT113. In the poster, JNJ‑95437446 reported preclinical findings that support its ongoing Phase 1 clinical development (
More news about: Whitehawk Therapeutics, Inc.
May 14, 2026, 16:01 ET Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
The survey was conducted by The Harris Poll on behalf of Johnson & Johnson (NYSE: JNJ) in collaboration with the International Bladder Cancer Group (IBCG), the World Bladder Cancer Patient Coalition (WBCPC), and the Bladder Cancer Advocacy
More news about: Johnson & Johnson
May 11, 2026, 08:00 ET Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
MeetingsTITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at
More news about: Johnson & Johnson
May 07, 2026, 08:00 ET Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
NEW BRUNSWICK, N.J., May 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower
More news about: Johnson & Johnson
May 05, 2026, 08:05 ET Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
48.2 About JNJ-4804JNJ-4804 is an investigational co-antibody therapy designed to target both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), two inflammatory pathways involved in chronic immune-mediated diseases. JNJ-4804 is a fixed-dose combination
More news about: Johnson & Johnson
May 05, 2026, 08:05 ET Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
2026CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's
More news about: Johnson & Johnson
May 04, 2026, 08:00 ET CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
TITUSVILLE, N.J., May 4, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the first network meta-analysis (NMA) comparing CAPLYTA® (lumateperone) to FDA-approved atypical antipsychotics for add-on
More news about: Johnson & Johnson
Apr 27, 2026, 08:03 ET FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
anemiaSPRING HOUSE, Pa., April 27, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA)
More news about: Johnson & Johnson